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Background: Clostridium difficile infection (CDI) is a leading cause of healthcare-associated
diarrhea worldwide. In this study, risk factors associated with the development of
severe-complicated and recurrent outcomes in CDI patients in different age groups,
including the non-elderly, were assessed in a third-level hospital.
Methods: CDI cases were detected by clinical data and polymerase-chain-reaction (PCR).
Clinical, demographic, epidemiological, and microbiological risk factors for CDI were
evaluated.
Results: During the study period, 248 out of 805 patients with nosocomial diarrhea were
diagnosed with CDI and the majority were severe-complicated cases (87.90%). Female
gender (OR 3.19, 95% CI 1.19e8.55, p ¼ 0.02) and lymphoma (OR 3.95, 95% CI 1.03e15.13,
p ¼ 0.04) were risk factors for severe-complicated CDI. Mature adulthood (51e60 years) (OR
5.80, 95% CI 1.56e21.62, p ¼ 0.01), previous rifampicin use (OR 7.44, 95% CI 2.10e26.44,
p ¼ 0.00), and neoplasm (solid malignant neoplasm or hematological malignancies) (OR
4.12, 95% CI 1.01e16.83, p ¼ 0.04) were risk factors for recurrent infection. Autoimmune
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Please cite this article as: Tijerina-Rodrı́gue
difficile infection in a tertiary teaching hospp ¼ 0.04), lymphoma (OR 3.79, 95% CI 1.03e12.07, p ¼ 0.04) and previous colistin treatment
(OR 4.97, 95% CI 1.05e23.58, p ¼ 0.04) were risk factors for 30-day mortality.
Conclusion: Newly identified risk factors for recurrent CDI were rifampicin treatment and
age between 51 and 60 years; colistin treatment was identified as a risk factor for 30-day
mortality. Previously identified risk factors for severe-complicated CDI were confirmed,










































Clostridium difficile (recently reclassified as Clostridioides diffi-
cile) infection (CDI) is a leading cause of healthcare-
associated diarrhea worldwide. In 2011, there were an esti-
mated 453,000 infections and 29,000 deaths resulting from
CDI in the United States [1]. CDI may be a mild, self-limiting
disease or a severe, complicated, life-threatening or recur-
rent disease [2].
Since 2000, an increase in the overall incidence of CDI
has been highlighted by outbreaks of more severe disease
in the United States, Canada, England, some Asian coun-
tries, and Latin America, with rates five-fold higher in
patients older than 65 years. The emergence of the strain
C. difficile NAP1/BI/027 has been associated with an
increased incidence, more severe infection, a high recur-
rence rate after 8 weeks of resolution, and higher 30-day
mortality rates [3]. A limited number of effective antimi-
crobials have been approved for CDI treatment, and the
highly virulent NAP1/BI/027 strain complicates current
treatment protocols [2].
Known risk factors for acquiring CDI are advanced age (>65
years), the use of broad-spectrum antibiotics, extended hos-
pital stays, stay at the intensive care unit, infection with the
human immunodeficiency virus, cancer, leukemia, lym-
phoma, autoimmune disorders, pulmonary infections
(tuberculosis or pneumonia), gastrointestinal procedures,
arterial hypertension, and the use of immunosuppressive
drugs, antacids and steroids [4e9].
The present study aimed to identify risk factors associated
with the development of severe-complicated, and recurrent
outcomes in CDI patients of different age groups, including


















Study setting and population
This was a retrospective study at the Hospital Civil de Gua-
dalajara Fray Antonio Alcalde, a 1000-bed tertiary-care
teaching hospital. The hospital has 31 wards housed in four
separate buildings. The hospital provides services to Guada-
lajara in the state of Jalisco, Mexico, with approximately
30,000 admissions each year.
Patient demographics and CDI diagnosis
As part of the surveillance protocol for CDI, between
November 2013 and December 2015, all hospitalized patientsz L et al., Clinical charac
ital from Mexico, Biomeddiarrhea (3 or more depositions in the last 24 h with a Bristol
score of 6 or 7 or a recent hospitalization in the previous 12
weeks) were tested for C. difficile using the Cepheid Xpert C.
difficile/Epi test (Cepheid, Sunnyvale CA).
Epidemiological and clinical data were reviewed in medical
records from CDI patients
CDI was defined as complicated when one of the following
criteria were present: admission to the intensive care unit,
hypotensionwith or without the required use of vasopressors,
fever 38.5 C, ileus, significant abdominal distention, mental
status changes, white blood cell (WBC) count 35,000 cells/
mm3 or <2000 cells/mm3, or serum lactate levels >2.2 mmol/l
[10]. CDI was defined as severe because of hypoalbuminemia
(serum albumin <3 g/dl), WBC 15,000 cells/mm3, or abdom-
inal tenderness [10].
Cases not meeting the severe or complicated infection criteria
were classified as having mild to moderate CDI (without
additional symptoms)
Recurrent CDI was defined by the reoccurrence of diarrhea
associated with clinical and laboratory evidence of CDI within
eight weeks after completing therapy or resolution of the
initial CDI, [10]. The study was reviewed and approved by the
Ethics Committee of the “Hospital Civil de Guadalajara Fray
Antonio Alcalde.”
Statistical analyses
The patients were classified into the following age group:
11e20, 21e30, 31e40, 41e50, 51e60, and >60 years of age. For
the analyses of categorical variables, Pearson's chi-squared
and Fisher's exact tests were used; for continuous variables,
the ManneWhitney U test was used. The KruskaleWallis test
was performed for comparison between severe-complicated
and recurrent CDI, as well as NAP1/027-associated CDI, 30-
day, and 12-month mortality frequencies among age groups.
Amultivariable logistic regression was conducted over two
stages: a univariable analysis to identify significant associa-
tions between independent variables and outcomes. Odds
ratios with a 95% confidence interval were determined. Vari-
ables identified in the univariate analysis with odds ratios>1.0
and p < 0.25 were included in a binary logistic regression
model. Variables with a p < 0.05 were considered as inde-
pendent risk factors.
We examined multi-collinearity using linear regression to
study the tolerance index (Ti) and the variance inflation factor
(VIF) for the absence of multicollinearity issues between in-
dependent variables by the Statistical Package for the Social
Sciences (SPSS), software version 23.teristics associated with the severity of Clostridium [Clostridioides]
ical Journal, https://doi.org/10.1016/j.bj.2021.02.007
Table 1 Demographic and epidemiological characteristics


















Abdominal pain 115 47.13
Fever (>38 C) 103 42.21
Abdominal distention 102 41.80
Mucus in stool 102 41.80
Vomiting 37 15.16




White blood cells (>15,000 cells//mm3) 76 31.14
Comorbidities
Arterial hypertension 93 38.11
Kidney disease 84 34.40
Diabetes mellitus 77 31.55






Autoimmune disorder 6 2.46
Other 19 7.79
C. difficile strain characteristics
NAP1/027 strain 127 52.05
non- NAP1/027 117 47.95
Recurrence
At least one 22/84 26.19
Due to C. difficile NAP1/027 strain 10/22 45.45
Due to non-C. difficile NAP1/027 strain 12/22 54.55
Hospitalization
General ward (before and after diagnosis) 222 90.98
In the previous 12 weeks 124 50.82
Intensive Care Unit 20 9.01















(continued on next page)
Table 1 e (continued )
N %
Histamine blockers 14 5.73
Proton pump inhibitors (PPI) 204 83.61
Immunosuppressors 36 14.75







a Clinical data were available for 244 patients only.
b 2013 frequency was not included since only 2-month period data
was available for this year.
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Epidemiological and clinical data
During the study period, 805 patients presented with noso-
comial diarrhea, and 248 were confirmed to have CDI by PCR
(62.10% were males, and 75% were <60 years old). Most pa-
tients with CDI were young adults (age, 21e30 years; n ¼ 46,
18.85%) or mature adults (51e60 years of age; n ¼ 45, 18.44%)
[Table 1].
Most patients presented with severe-complicated disease
(87.70%). Hypoalbuminemia n ¼ 148, 60.65%), abdominal pain
(n ¼ 115, 47.13%), fever >38.5 C (n ¼ 103, 42.21%), abdominal
distension (n ¼ 102, 41.80%), and mucus in stool (n ¼ 102,
41.80%) were the most common signs and symptoms associ-
ated with CDI. The most frequently observed comorbidities
were arterial hypertension (n ¼ 93, 38.11%), kidney disease,
including patients that presented urinary infection or creati-
nine levels >1.5 mg/dl (n ¼ 84, 34.40%), and diabetes (n ¼ 77,
31.55%) [Table 1].
The hypervirulent C. difficile NAP1/027 strain was detected
in 127 (52.04%) patients, and 84 of these patients were fol-
lowed for the next eight weeks; among them, 22 patients
(26.19%) developed at least one recurrent episode. From the
recurrent episodes, 10/22 (45.40%) were caused by the C. diffi-
cile NAP1/027 strain and 12/22 (54.50%) by a non-NAP1/027
strain.
Most patients (n ¼ 222) were housed in the general ward,
and among them, 124 had been hospitalized during the 12
weeks previous to CDI. Twenty patients had been admitted to
the intensive care unit when CDI was diagnosed. The
remaining two patients were in other wards. All patients with
the first episode of mild to moderate CDI were treated with
metronidazole, and recurrent episodes were treated with
metronidazole in combination with vancomycin according to
the American College of Gastroenterology guidelines and the
Guidelines for C. difficile Infection in Adults and Children of the
Infectious Diseases Society of America (IDSA) and Society for
Healthcare Epidemiology of America (SHEA). Second-line
therapies, such as fidaxomicin treatment or a fecal micro-
biota transplant, were not used due to their unavailability at
that time in our hospital.eristics associated with the severity of Clostridium [Clostridioides]
ical Journal, https://doi.org/10.1016/j.bj.2021.02.007
Table 2 Risk factors for the development of severity, recurrence, and 30-day mortality.
Dependent Variable Univariate analysis Binary logistic regression
U-ORd (95% CI) p-value A-ORe (95% CI) p-value
Severe CDIa Gender (females) 2.58 (1.00e6.51) 0.03* 3.19 (1.19e8.55) 0.02*
Lymphoma 1.33 (0.89e1.99) 0.04* 3.95 (1.03e15.13) 0.04*
Age (21e30 years) 1.51 (0.98e1.35) 0.03* 2.41 (1.00e5.78) 0.05
Infection with 027 strain 1.67 (0.77e3.64) 0.13 0.56 (0.25e1.26) 0.16
Recurrenceb Age (51e60 years) 6.54 (2.07e20.68) 0.00** 5.80 (1.56e21.62) 0.01*
Antibiotics intake 2.19 (0.57e8.44) 0.19 1.42 (0.31e6.43) 0.64
Rifampin 4.37 (0.89e21.37) 0.07 7.44 (2.10e26.44) 0.00**
Neoplasm 2.42 (0.79e7.47) 0.10 4.12 (1.01e16.83) 0.04*
Fluoroquinolones 2.74 (0.74e10.12) 0.11 2.55 (0.55e11.73) 0.23
Hypertension 1.23 (0.46e3.29) 0.67 1.62 (0.48e5.49) 0.23
30-day-mortalityc Autoimmune disorder 5.09 (0.97e26.24) 0.03* 6.62 (1.26e34.73) 0.02*
Leukemia 3.90 (0.84e18.24) 0.09 4.97 (1.05e23.58) 0.04*
Lymphoma 2.62 (0.75e9.21) 0.12 3.79 (1.03e12.07) 0.04*
Colistin 3.79 (0.81e17.70) 0.10 4.97 (1.05e23.58) 0.04*
Goodness of fit test: Hosmer y Lemeshow, a x2 ¼ 3.878, p ¼ 0.567, b x2 ¼ 4.657, p ¼ 0.702, c x2¼ 0.167, p ¼ 0.683. *p < 0.05, **p < 0.01. d Unadjusted odds-
ratio, e Adjusted odds-ratio.





















































































































BJ398_proof ■ 27 February 2021 ■ 4/6Almost two-thirds of the patients had previously received
antibiotic treatment (n ¼ 165, 67.62%), most commonly clin-
damycin (n¼ 128, 77.58%) and cephalosporins (n¼ 89, 53.94%);
metronidazole and vancomycinwere previously administered
in 21.21% and 11.52% of the cases, respectively which are
usually administered for CDI treatment [Table 1]. From the
CDI 248 cases, 3 (1.21%) occurred in 2013, 68 (27.42%) in 2014,
and 177 (71.37%) in 2015.
Risk factors detected for CDI
Female gender (OR 3.19, 95% CI 1.19e8.55, p ¼ 0.02) and lym-
phoma (OR 3.95, 95%CI 1.03e15.13, p¼ 0.04) were independent
risk factors for severe CDI [Table 2].
Mature adulthood (51e60 years) (OR 5.80, 95% CI
1.56e21.62, p ¼ 0.01), rifampin consumption (OR 7.44, 95% CI
2.10e26.44, p¼ 0.00) and neoplasm (solid malignant neoplasm
or hematological malignancies) (OR 4.12, 95% CI 1.01e16.83,
p¼ 0.04) were independent risk factors for the development of
recurrent CDI [Table 2].
We identified the following independent risk factors for 30-
day mortality rates: autoimmune disorders (OR 6.62, CI 95%
1.26e34.73, p ¼ 0.02), leukemia (OR 4.97, 95% CI 1.05e23.58,
p ¼ 0.04), lymphoma (OR 3.79, CI 95% 1.03e12.07, p ¼ 0.04) and
previous colistin treatment (OR 4.97, 95% CI 1.05e23.58,















Our study addressed risk factors among patients with CDI,
and we detected that 89.0% of the patients developed severe
CDI. In contrast to previous reports that identified the elderly
(>60 years) to be the most vulnerable age group [3,11e16], in
our study, young (age 21e30 years) andmature adulthood (age
51e60 years) adults had the highest frequency of CDI,
respectively 18.55% and 18.15%. Previous studies conducted in
Mexico reported that patients <65 years of age had a higher
risk of recurrent CDI [17e19]. This Mexican study identifiedPlease cite this article as: Tijerina-Rodrı́guez L et al., Clinical charac
difficile infection in a tertiary teaching hospital from Mexico, Biomedmature adulthood (51e60 years) as an independent risk factor
for the development of recurrent CDI. The different conclu-
sions with respect to the most vulnerable age group may be
explained by the fact that most CDI surveillance studies have
focused primarily on the elderly, excluding younger adults
and children [3,20,21]. Furthermore, the healthcare facility
where the study was conducted also provided medical atten-
tion mainly to traumatized younger patients and was better
equipped to identify this novel, at-risk population.
The prevalence of the NAP1/027 C. difficile strain in about
half of our CDI patients is consistent with reports from other
countries where prevalence was between 45 and 61% [19].
The present study confirmed previously described risk
factors for complicated or recurrent CDI [3,12,22,23], e.g.,
middle-aged adulthood and neoplasm illness were indepen-
dent risk factors for recurrent CDI, whereas lymphomawas an
independent risk factor for complicated CDI.
As far as we know, we are the first to report that rifampin
and colistin are independent risk factors for recurrent CDI and
30-daymortality, respectively. It should be noted, though, that
only seven patients received colistin therapy before the CDI
diagnosis. This risk factor is significant because recent studies
have reported infections due to multidrug-resistant strains
that were only susceptible to colistin. This antibiotic was not
used until recently because of its nephrotoxicity. However,
during the last decade, it has been reintroduced to treat crit-
ical illnesses such as pneumonia, bacteremia, meningitis,
obstructive pulmonary disease, and cystic fibrosis [24e26].
However, in the treatment of pneumonia, bacteremia, and
other critical diseases related to the development of CDI, a
high mortality rate (61.9%) has been attributed to colistin
therapy (OR, 1.99 to 8.2; p < 0.001) [24,25].
It should be mentioned that our hospital had an outbreak
of carbapenem-resistant enterobacteria during the study
period; thus, the use of tigecycline and colistin was increased.
Regarding colistin as an independent risk factor for mortality,
we must consider that these patients had severe clinical
conditions, and the high mortality rate may be due to the
underlying infection. In this regard, a prediction model usingteristics associated with the severity of Clostridium [Clostridioides]
ical Journal, https://doi.org/10.1016/j.bj.2021.02.007
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BJ398_proof ■ 27 February 2021 ■ 5/6logistic regression for CDI in hospitalized patients identified
an underlying infection as an independent predictor of CDI
[27].
Still, this newly described risk factor for the development
of CDI reinforced the need for control of other hospital-
acquired infectious diseases as an additional means of pre-
venting CDI. As a result, in our hospital, quinolone was
reduced, and the use of levofloxacin was eliminated from
almost all wards except for the hematology and urology
wards.
We used the Xpert C. difficile/Epi assay to confirm CDI. This
assay detects the genes tcdB and cdt and the 18-bp deletion in
tcdC, but it does not identify the tcdA gene. Therefore, it is
possible that patients infectedwith strains that only produced
tcdA were not identified. On the other hand, it seems that the
production of only toxin A is rare. A study that compared CDI
detection by either the Xpert C. difficile with detection by the
tcdA-based Illumigene C. difficile assay (Meridian Bioscience,
Inc.) found that 157 samples were negative in both tests, 35
were positive in both assays, 7 were positive by GeneXpert but
negative by the Illumigene assay, and in one case, the Gen-
expert was positive. However, the result of illumigene was
invalid [28]. Thus, the lack of detection of tcdA by the Gen-
eXpert may have had a minimal effect in our study.
The major limitation of our study was that it was per-
formed at a single site, and results may not apply to other
hospitals. The high number of complicated CDI infections in
our hospital and their associated risk factors may be advo-
cated by increased infections caused by carbapenem-resistant












In summary, in our study, CDI was mainly prevalent among
patients <60 years, who were also more vulnerable to severe
CDI. The use of colistin was identified as a new risk factor for
increased 30-day mortality rates, while the use of rifampin
treatment was a new risk factor for the development of
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